Metildopa etkileşimleri

antihipertansif sınıfından Metildopa (Aldomet) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 244 belgelenmiş etkileşim var: 17 majör, 141 orta, 86 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 0 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Majör etkileşimler (17)

  • Deferasiroksdemir takviyesiMajör

    Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. (Metildopa etiketi, İlaç etkileşimleri)

  • Deferiprondemir takviyesiMajör

    Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. (Metildopa etiketi, İlaç etkileşimleri)

  • DemirVitamin ve mineralMajör

    Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. (Metildopa etiketi, İlaç etkileşimleri)

  • Eptifibatidantitrombosit ilaçMajör

    …of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (Eptifibatid etiketi, Kontrendikasyonlar)

  • FenelzinMAO inhibitörüMajör

    CONTRAINDICATIONS Methyldopa is contraindicated in patients: – with active hepatic disease, such as acute hepatitis and active cirrhosis. – with liver disorders previously associated with methyldopa therapy (see WARNINGS ). – with hypersensitivity to any component of this product. – on therapy with monoamine oxidase (MAO) inhibitors. (Metildopa etiketi, Kontrendikasyonlar)

  • Ferrik sitratfosfat bağlayıcıMajör

    Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. (Metildopa etiketi, İlaç etkileşimleri)

  • • Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs ( 7.2 ) (Hiyalüronidaz etiketi, İlaç etkileşimleri)

  • İzoniazidantibiyotikMajör

    CONTRAINDICATIONS Methyldopa is contraindicated in patients: – with active hepatic disease, such as acute hepatitis and active cirrhosis. – with liver disorders previously associated with methyldopa therapy (see WARNINGS ). – with hypersensitivity to any component of this product. – on therapy with monoamine oxidase (MAO) inhibitors. (Metildopa etiketi, Kontrendikasyonlar)

  • KlozapinantipsikotikMajör

    Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (Klozapin etiketi, Kutulu uyarı)

  • LinezolidantibiyotikMajör

    CONTRAINDICATIONS Methyldopa is contraindicated in patients: – with active hepatic disease, such as acute hepatitis and active cirrhosis. – with liver disorders previously associated with methyldopa therapy (see WARNINGS ). – with hypersensitivity to any component of this product. – on therapy with monoamine oxidase (MAO) inhibitors. (Metildopa etiketi, Kontrendikasyonlar)

  • Metilen mavisiMAO inhibitörüMajör

    CONTRAINDICATIONS Methyldopa is contraindicated in patients: – with active hepatic disease, such as acute hepatitis and active cirrhosis. – with liver disorders previously associated with methyldopa therapy (see WARNINGS ). – with hypersensitivity to any component of this product. – on therapy with monoamine oxidase (MAO) inhibitors. (Metildopa etiketi, Kontrendikasyonlar)

  • Metolazontiyazid diüretikMajör

    Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (Metolazon etiketi, Uyarılar)

  • MinoksidilvazodilatörMajör

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (Minoksidil etiketi, Kutulu uyarı)

  • RasajilinMAO inhibitörüMajör

    CONTRAINDICATIONS Methyldopa is contraindicated in patients: – with active hepatic disease, such as acute hepatitis and active cirrhosis. – with liver disorders previously associated with methyldopa therapy (see WARNINGS ). – with hypersensitivity to any component of this product. – on therapy with monoamine oxidase (MAO) inhibitors. (Metildopa etiketi, Kontrendikasyonlar)

  • SelejilinMAO inhibitörüMajör

    CONTRAINDICATIONS Methyldopa is contraindicated in patients: – with active hepatic disease, such as acute hepatitis and active cirrhosis. – with liver disorders previously associated with methyldopa therapy (see WARNINGS ). – with hypersensitivity to any component of this product. – on therapy with monoamine oxidase (MAO) inhibitors. (Metildopa etiketi, Kontrendikasyonlar)

  • TadalafilPDE5 inhibitörüMajör

    …coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (Tadalafil etiketi, Uyarılar ve önlemler)

  • TranilsiprominMAO inhibitörüMajör

    CONTRAINDICATIONS Methyldopa is contraindicated in patients: – with active hepatic disease, such as acute hepatitis and active cirrhosis. – with liver disorders previously associated with methyldopa therapy (see WARNINGS ). – with hypersensitivity to any component of this product. – on therapy with monoamine oxidase (MAO) inhibitors. (Metildopa etiketi, Kontrendikasyonlar)

Orta düzey etkileşimler (141)

  • AdrenalinsempatomimetikOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • Alfuzosinalfa blokerOrta

    Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (Alfuzosin etiketi, Uyarılar ve önlemler)

  • AripiprazolantipsikotikOrta

    Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (Aripiprazol etiketi, İlaç etkileşimleri)

  • ArmodafinilMSS uyarıcısıOrta

    There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (Armodafinil etiketi, Uyarılar ve önlemler)

  • Artikain ve adrenalinlokal anestezikOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • AsenapinantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Asenapin etiketi, Uyarılar ve önlemler)

  • Atenololbeta blokerOrta

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (Atenolol etiketi, Uyarılar)

  • Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (Atenolol ve klortalidon etiketi, Uyarılar)

  • Atomoksetinnoradrenalin geri alım inhibitörüOrta

    Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (Atomoksetin etiketi, İlaç etkileşimleri)

  • AvanafilPDE5 inhibitörüOrta

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

  • Azelastin ve flutikazonantihistaminikOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • BeklometazonkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • The thiazide component of Lotensin HCT may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic-blocking drugs. (Benazepril ve hidroklorotiyazid etiketi, Uyarılar)

  • BenzfetaminMSS uyarıcısıOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • BetametazonkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • Bisoprololbeta blokerOrta

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol etiketi, Uyarılar)

  • Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (Bisoprolol ve hidroklorotiyazid etiketi, Uyarılar)

  • Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • BrekspiprazolantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Brekspiprazol etiketi, Uyarılar ve önlemler)

  • Brimonidinalfa adrenerjik agonistOrta

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (Brimonidin etiketi, İlaç etkileşimleri)

  • Brimonidin ve timololalfa adrenerjik agonistOrta

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. (Brimonidin ve timolol etiketi, İlaç etkileşimleri)

  • If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • Bromokriptindopamin agonistiOrta

    Use caution in patients taking antihypertensive medications. (Bromokriptin etiketi, Uyarılar ve önlemler)

  • BudesonidkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • Budesonid ve formoterolkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • Bumetanidkıvrım (loop) diüretiğiOrta

    Antihypertensives Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. (Bumetanid etiketi, İlaç etkileşimleri)

  • Bupivakain ve adrenalinlokal anestezikOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • DeflazakortkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • DeksametazonkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • DeksmetilfenidatMSS uyarıcısıOrta

    • Antihypertensive Drugs: Monitor blood pressure. (Deksmetilfenidat etiketi, İlaç etkileşimleri)

  • Desflurangenel anestezikOrta

    Patients may require reduced doses of anesthetics when on methyldopa. (Metildopa etiketi, İlaç etkileşimleri)

  • DesonidkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • DietilpropionMSS uyarıcısıOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • DiklofenakNSAİİOrta

    Intervention: During concomitant use of ZIPSOR with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (Diklofenak etiketi, İlaç etkileşimleri)

  • Intervention: During concomitant use of diclofenac sodium/misoprostol with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions (5.7) ] . (Diklofenak ve misoprostol etiketi, İlaç etkileşimleri)

  • DobutaminsempatomimetikOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • DroksidopasempatomimetikOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • DuloksetinSNRIOrta

    The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (Duloksetin etiketi, Uyarılar ve önlemler)

  • EfedrinsempatomimetikOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • Therefore, drugs known to be metabolized by COMT, such as isoproterenol, epinephrine, norepinephrine, dopamine, dobutamine, alpha-methyldopa, apomorphine, isoetherine, and bitolterol should be administered with caution in patients receiving entacapone regardless of the route of administration (including inhalation), as their interaction may result in increased… (Entakapon etiketi, Uyarılar)

  • Eplerenonaldosteron antagonistiOrta

    The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function. (Eplerenon etiketi, İlaç etkileşimleri)

  • Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Epoetin alfa etiketi, Uyarılar ve önlemler)

  • Epoprostenolprostaglandin analoğuOrta

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Epoprostenol etiketi, İlaç etkileşimleri)

  • Esmololbeta blokerOrta

    Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. (Esmolol etiketi, İlaç etkileşimleri)

  • Etomidatgenel anestezikOrta

    Patients may require reduced doses of anesthetics when on methyldopa. (Metildopa etiketi, İlaç etkileşimleri)

  • FendimetrazinMSS uyarıcısıOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • FenilefrindekonjestanOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • FenoprofenNSAİİOrta

    Intervention: During concomitant use of FENOPROFEN CALCIUM with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (Fenoprofen etiketi, İlaç etkileşimleri)

  • FenterminMSS uyarıcısıOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • FludrokortizonkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • FlunisolidkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • FluosinonidkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • FlurbiprofenNSAİİOrta

    Intervention: During concomitant use of flurbiprofen with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions (5) ]. (Flurbiprofen etiketi, İlaç etkileşimleri)

  • FlutikazonkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • Flutikazon ve salmeterolkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • The thiazide component of fosinopril sodium and hydrochlorothiazide may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic-blocking drugs. (Fosinopril ve hidroklorotiyazid etiketi, Uyarılar)

  • Furosemidkıvrım (loop) diüretiğiOrta

    Monitor for changes in blood pressure and adjust the dose of other antihypertensive drugs if needed. (Furosemid etiketi, İlaç etkileşimleri)

  • HalobetazolkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • During concomitant use of hydrocodone bitartrate and ibuprofen tablets with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects (see WARNINGS: Renal Toxicity and Hyperkalemia ). (Hidrokodon ve ibuprofen etiketi, İlaç etkileşimleri)

  • HidrokortizonkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • İbuprofenNSAİİOrta

    Intervention: During concomitant use of CALDOLOR with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (İbuprofen etiketi, İlaç etkileşimleri)

  • Intervention: During concomitant use of ibuprofen and famotidine tablet with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.7 )] . (İbuprofen ve famotidin etiketi, İlaç etkileşimleri)

  • İloperidonantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (İloperidon etiketi, Uyarılar ve önlemler)

  • İndapamidtiyazid diüretikOrta

    Drug Interactions Other Antihypertensives: Indapamide may add to or potentiate the action of other antihypertensive drugs. (İndapamid etiketi, İlaç etkileşimleri)

  • İndometazinNSAİİOrta

    Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7 ) (İndometazin etiketi, İlaç etkileşimleri)

  • İzoflurangenel anestezikOrta

    Patients may require reduced doses of anesthetics when on methyldopa. (Metildopa etiketi, İlaç etkileşimleri)

  • İzoprenalinbeta adrenerjik agonistOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (Karbidopa etiketi, İlaç etkileşimleri)

  • Karbidopa ve levodopadopaminerjik ilaçOrta

    Antihypertensive drugs: May cause symptomatic postural hypotension. (Karbidopa ve levodopa etiketi, İlaç etkileşimleri)

  • Karbidopa, levodopa ve entakapondopaminerjik ilaçOrta

    Interaction with Drugs Metabolized by COMT Drugs known to be metabolized by COMT, such as isoproterenol, epinephrine, norepinephrine, dopamine, dobutamine, alpha-methyldopa, apomorphine, isoetherine, and bitolterol should be administered with caution in patients receiving entacapone regardless of the route of administration (including inhalation), as their interaction… (Karbidopa, levodopa ve entakapon etiketi, Uyarılar ve önlemler)

  • KariprazinantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Kariprazin etiketi, Uyarılar ve önlemler)

  • Karvedilolbeta blokerOrta

    COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

  • KetaminMSS depresanıOrta

    Patients may require reduced doses of anesthetics when on methyldopa. (Metildopa etiketi, İlaç etkileşimleri)

  • KetiapinantipsikotikOrta

    Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Ketiapin etiketi, Uyarılar ve önlemler)

  • Kinapril ve hidroklorotiyazidACE inhibitörüOrta

    The thiazide component of quinapril and hydrochlorothiazide tablets may potentiate the action of other antihypertensive drugs, especially ganglionic or peripheral adrenergic- blocking drugs. (Kinapril ve hidroklorotiyazid etiketi, Uyarılar)

  • KlobetazolkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • Klorotiyazidtiyazid diüretikOrta

    Thiazides may add to or potentiate the action of other antihypertensive drugs. (Klorotiyazid etiketi, Uyarılar)

  • Klortalidontiyazid diüretikOrta

    Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (Klortalidon etiketi, İlaç etkileşimleri)

  • Lidokain ve adrenalinlokal anestezikOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed (see DOSAGE AND ADMINISTRATION ). (Lisinopril ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • Lityumserotonerjik ilaçOrta

    When methyldopa and lithium are given concomitantly, the patient should be carefully monitored for symptoms of lithium toxicity. (Metildopa etiketi, İlaç etkileşimleri)

  • LumateperonantipsikotikOrta

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Lumateperon etiketi, Uyarılar ve önlemler)

  • LurasidonantipsikotikOrta

    Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (Lurasidon etiketi, Uyarılar ve önlemler)

  • Mefenamik asitNSAİİOrta

    Intervention: During concomitant use of mefenamic acid with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions ( 5.6 )] . (Mefenamik asit etiketi, İlaç etkileşimleri)

  • MekamilaminantihipertansifOrta

    The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (Mekamilamin etiketi, İlaç etkileşimleri)

  • MeloksikamNSAİİOrta

    Intervention: During concomitant use of QAMZOVA with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (Meloksikam etiketi, İlaç etkileşimleri)

  • MetamfetaminMSS uyarıcısıOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • MetilfenidatMSS uyarıcısıOrta

    Antihypertensive Drugs: Monitor blood pressure. (Metilfenidat etiketi, İlaç etkileşimleri)

  • MetilprednizolonkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • MetoheksitalbarbitüratOrta

    Patients may require reduced doses of anesthetics when on methyldopa. (Metildopa etiketi, İlaç etkileşimleri)

  • Midodrinalfa adrenerjik agonistOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • Mirabegronbeta adrenerjik agonistOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • MirtazapinantidepresanOrta

    REMERON/REMERONSolTab should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke) and conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medication). (Mirtazapin etiketi, Uyarılar ve önlemler)

  • ModafinilMSS uyarıcısıOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • MometazonkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • NaproksenNSAİİOrta

    ( 5.3 Hepatotoxicity) Hypertension: Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Naproksen etiketi, Uyarılar ve önlemler)

  • Intervention : During concomitant use of naproxen and esomeprazole magnesium delayed-release tablets with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see Warnings and Precautions (5.6) ]. (Naproksen ve esomeprazol etiketi, İlaç etkileşimleri)

  • NiasinOrta

    Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (Niasin etiketi, İlaç etkileşimleri)

  • Nifedipindihidropiridin kalsiyum kanal blokeriOrta

    Other Diuretics, PDE5 inhibitors, alpha-methyldopa: Nifedipine may increase the blood pressure lowering effect of these concomitantly administered agents. (Nifedipin etiketi, İlaç etkileşimleri)

  • Nimodipindihidropiridin kalsiyum kanal blokeriOrta

    Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (Nimodipin etiketi, İlaç etkileşimleri)

  • NitrogliserinnitratOrta

    Antihypertensives: Possible additive hypotensive effects. (Nitrogliserin etiketi, İlaç etkileşimleri)

  • OksaprozinNSAİİOrta

    Intervention: During concomitant use of OXAPROZIN CAPSULES with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [see WARNINGS AND PRECAUTIONS (5.6) ]. (Oksaprozin etiketi, İlaç etkileşimleri)

  • OksimetazolindekonjestanOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • OlanzapinantipsikotikOrta

    …of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (Olanzapin etiketi, Uyarılar ve önlemler)

  • Olanzapin ve fluoksetinantipsikotikOrta

    …and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Olanzapin ve fluoksetin etiketi, Uyarılar ve önlemler)

  • Olopatadin ve mometazonantihistaminikOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • PaliperidonantipsikotikOrta

    Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (Paliperidon etiketi, Uyarılar ve önlemler)

  • • Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Parasetamol ve ibuprofen etiketi, Uyarılar ve önlemler)

  • Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib etiketi, Uyarılar ve önlemler)

  • PentoksifilinmetilksantinOrta

    Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (Pentoksifilin etiketi, İlaç etkileşimleri)

  • PiroksikamNSAİİOrta

    Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Piroksikam etiketi, İlaç etkileşimleri)

  • Prazosinalfa blokerOrta

    Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (Prazosin etiketi, Uyarılar)

  • PrednizolonkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • PrednizonkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • Prilokain ve adrenalinlokal anestezikOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • PropofolMSS depresanıOrta

    Patients may require reduced doses of anesthetics when on methyldopa. (Metildopa etiketi, İlaç etkileşimleri)

  • PsödoefedrindekonjestanOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • RiosiguatvazodilatörOrta

    Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (Riosiguat etiketi, Uyarılar ve önlemler)

  • RisperidonantipsikotikOrta

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (Risperidon etiketi, Uyarılar ve önlemler)

  • SelekoksibNSAİİOrta

    Intervention: During concomitant use of VYSCOXA with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions (5.6) ]. (Selekoksib etiketi, İlaç etkileşimleri)

  • Sevoflurangenel anestezikOrta

    Patients may require reduced doses of anesthetics when on methyldopa. (Metildopa etiketi, İlaç etkileşimleri)

  • SiklesonidkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • Siklobenzaprinkas gevşeticiOrta

    …concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (Siklobenzaprin etiketi, İlaç etkileşimleri)

  • SiklosporinimmünosüpresanOrta

    If hypertension persists, the dose of Neoral should be further reduced or blood pressure should be controlled with antihypertensive agents. (Siklosporin etiketi, Önlemler)

  • SildenafilPDE5 inhibitörüOrta

    Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (Sildenafil etiketi, Uyarılar ve önlemler)

  • Silodosinalfa blokerOrta

    However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (Silodosin etiketi, Uyarılar ve önlemler)

  • Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

  • Spironolakton ve hidroklorotiyazidaldosteron antagonistiOrta

    Thiazides may add to or potentiate the action of other antihypertensive drugs. (Spironolakton ve hidroklorotiyazid etiketi, Uyarılar)

  • Monitor patients to assure diuretic efficacy including antihypertensive effects. (Sumatriptan ve naproksen etiketi, İlaç etkileşimleri)

  • Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib etiketi, Uyarılar ve önlemler)

  • TakrolimusimmünosüpresanOrta

    • Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (Takrolimus etiketi, Uyarılar ve önlemler)

  • Terazosinalfa blokerOrta

    Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (Terazosin etiketi, Uyarılar ve önlemler)

  • TestosteronandrojenOrta

    In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (Testosteron etiketi, Uyarılar ve önlemler)

  • TrazodonantidepresanOrta

    Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (Trazodon etiketi, Uyarılar ve önlemler)

  • TriamsinolonkortikosteroidOrta

    If not, corticosteroids may be given and other causes of anemia should be considered. (Metildopa etiketi, Uyarılar)

  • Triamteren ve hidroklorotiyazidpotasyum tutucu diüretikOrta

    Thiazides may add to or potentiate the action of other antihypertensive drugs. (Triamteren ve hidroklorotiyazid etiketi, İlaç etkileşimleri)

  • VardenafilPDE5 inhibitörüOrta

    Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (Vardenafil etiketi, İlaç etkileşimleri)

  • Drugs Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasostrict ® . (Vazopressin etiketi, İlaç etkileşimleri)

  • VenlafaksinSNRIOrta

    Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Venlafaksin etiketi, İlaç etkileşimleri)

  • Vibegronbeta adrenerjik agonistOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • ZiprasidonantipsikotikOrta

    Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Ziprasidon etiketi, Uyarılar ve önlemler)

Minör değinmeler (86)

  • AliskirenantihipertansifMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Amiloridpotasyum tutucu diüretikMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Amlodipindihidropiridin kalsiyum kanal blokeriMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Amlodipin ve atorvastatindihidropiridin kalsiyum kanal blokeriMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Amlodipin ve benazeprildihidropiridin kalsiyum kanal blokeriMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Amlodipin ve olmesartandihidropiridin kalsiyum kanal blokeriMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Amlodipin ve valsartandihidropiridin kalsiyum kanal blokeriMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Asebutololbeta blokerMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Azilsartananjiyotensin II reseptör blokeri (ARB)Minör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • BenazeprilACE inhibitörüMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Betaksololbeta blokerMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • ButorfanolopioidMinör

    In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (Butorfanol etiketi, Uyarılar)

  • DekstroamfetaminMSS uyarıcısıMinör

    Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (Dekstroamfetamin etiketi, İlaç etkileşimleri)

  • Desipramintrisiklik antidepresanMinör

    This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting compounds. (Desipramin etiketi, Uyarılar)

  • Desogestrel ve etinilestradioloral kontraseptifMinör

    If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (Desogestrel ve etinilestradiol etiketi, Uyarılar)

  • DiflunisalNSAİİMinör

    Drug Interactions ACE-inhibitors and Angiotensin II Anagonists Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors and angiotensin II antagonists. (Diflunisal etiketi, İlaç etkileşimleri)

  • Diltiazemkalsiyum kanal blokeriMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Doksazosinalfa blokerMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • EnalaprilACE inhibitörüMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Enalapril ve hidroklorotiyazidACE inhibitörüMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • EnalaprilatACE inhibitörüMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Etakrinik asitkıvrım (loop) diüretiğiMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • EtodolakNSAİİMinör

    Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Etodolak etiketi, İlaç etkileşimleri)

  • Felodipindihidropiridin kalsiyum kanal blokeriMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Fenoksibenzaminalfa blokerMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • FosinoprilACE inhibitörüMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Guanfasinalfa adrenerjik agonistMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • HidralazinvazodilatörMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Hidroklorotiyazidtiyazid diüretikMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (İkatibant etiketi, İlaç etkileşimleri)

  • İrbesartananjiyotensin II reseptör blokeri (ARB)Minör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • İrbesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • İsradipindihidropiridin kalsiyum kanal blokeriMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Kandesartananjiyotensin II reseptör blokeri (ARB)Minör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Kandesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • KaptoprilACE inhibitörüMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • KetoprofenNSAİİMinör

    ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

  • KetorolakNSAİİMinör

    Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors and/or angiotensin II receptor antagonists. (Ketorolak etiketi, İlaç etkileşimleri)

  • KinaprilACE inhibitörüMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Klonidinalfa adrenerjik agonistMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • KlorpromazinantipsikotikMinör

    Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

  • Kolestipolsafra asidi bağlayıcıMinör

    No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin. (Kolestipol etiketi, İlaç etkileşimleri)

  • Labetalolbeta blokerMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • LisinoprilACE inhibitörüMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Lofeksidinalfa adrenerjik agonistMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Losartananjiyotensin II reseptör blokeri (ARB)Minör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Losartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • MeksiletinantiaritmikMinör

    In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (Meksiletin etiketi, İlaç etkileşimleri)

  • Metoprololbeta blokerMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • MoeksiprilACE inhibitörüMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • NabumetonNSAİİMinör

    Drug Interactions: ACE-inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Nabumeton etiketi, İlaç etkileşimleri)

  • Nadololbeta blokerMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Nebivololbeta blokerMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Nikardipindihidropiridin kalsiyum kanal blokeriMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Nisoldipindihidropiridin kalsiyum kanal blokeriMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • NitroprussidvazodilatörMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Nortriptilintrisiklik antidepresanMinör

    The antihypertensive action of guanethidine and similar agents may be blocked. (Nortriptilin etiketi, Uyarılar)

  • Olmesartananjiyotensin II reseptör blokeri (ARB)Minör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Olmesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Olmesartan, amlodipin ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • PerindoprilACE inhibitörüMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Pindololbeta blokerMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • ProklorperazinantipsikotikMinör

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. (Proklorperazin etiketi, Önlemler)

  • Propranololbeta blokerMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Protriptilintrisiklik antidepresanMinör

    Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (Protriptilin etiketi, Uyarılar)

  • RamiprilACE inhibitörüMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • RiluzolMinör

    Hepatotoxic Drugs Clinical trials in ALS patients excluded patients on concomitant medications which were potentially hepatotoxic (e.g., allopurinol, methyldopa, sulfasalazine). (Riluzol etiketi, İlaç etkileşimleri)

  • Sakubitril ve valsartananjiyotensin II reseptör blokeri (ARB)Minör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • SalsalatNSAİİMinör

    DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Salsalat etiketi, İlaç etkileşimleri)

  • Spironolaktonaldosteron antagonistiMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • SulindakNSAİİMinör

    Drug Interactions ACE-Inhibitors and Angiotensin II Antagonists Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors and angiotensin II antagonists. (Sulindak etiketi, İlaç etkileşimleri)

  • Telmisartananjiyotensin II reseptör blokeri (ARB)Minör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Telmisartan ve amlodipinanjiyotensin II reseptör blokeri (ARB)Minör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Telmisartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Tizanidinkas gevşeticiMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • TolkaponMinör

    The effect of tolcapone on the pharmacokinetics of other drugs of this class such as α-methyldopa, dobutamine, apomorphine, and isoproterenol has not been evaluated. (Tolkapon etiketi, İlaç etkileşimleri)

  • TolmetinNSAİİMinör

    DRUG INTERACTIONS ACE Inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE Inhibitors. (Tolmetin etiketi, İlaç etkileşimleri)

  • Torasemidkıvrım (loop) diüretiğiMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • TrandolaprilACE inhibitörüMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Triamterenpotasyum tutucu diüretikMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • TrifluoperazinantipsikotikMinör

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. (Trifluoperazin etiketi, Önlemler)

  • Valsartananjiyotensin II reseptör blokeri (ARB)Minör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Valsartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Minör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

  • Verapamilkalsiyum kanal blokeriMinör

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (Metildopa etiketi, İlaç etkileşimleri)

Kullandığınız her şeyi Metildopa ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.